http://papillarythyroidcancer.tripod.com/
Renal Cell Carcinoma Drug Might Assist Battle Papillary Thyroid Most cancers
A drug accustomed to treat advanced renal cell carcinoma was tolerated well in papillary thyroid cancer patients during its Phase II trial, based on study results published within the March online edition from the Journal of Clinical Oncology.
Sorafenib, referred to as Nexavar, is FDA-approved to deal with a sophisticated stage of kidney cancer called renal cell carcinoma. This recent study says the drug also may help fight papillary thyroid cancer.
Pitt University Researchers assessed bi-monthly responses in 41 papillary thyroid cancer patients assigned 400 mg of sorafenib twice each day. Patients were split up into two groups: Arm A, which required a tumor for biopsy, and Arm B, who had subtypes of carcinoma and didn't require tumor biopsy.
Overall study findings figured 23 from the 41 patients were built with a stable disease condition for over 6 months. Median progression-free survival was 15 months. Common negative effects were fatigue, musculoskeletal pain and hand-foot skin reaction.
No comments:
Post a Comment